Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Republican Strategy To Protect Part D Raises Risks For Pharma

Executive Summary

House Oversight and Government Reform Committee Republicans are attempting to deflect criticism of Medicare Part D drug expenditures by redirecting focus back to larger expenditures under Parts A and B

You may also be interested in...



Baucus Proposes Medicare Part D Drugs For Duals Be Reimbursed At Medicaid Rates

Proposal offered by Senate Finance Committee chairman in health care reform white paper follows path Rep. Waxman is expected to take with legislation early next year.

Waxman to seek Medicaid prices for dual eligbles

Legislation that would set Medicare Part D drug prices paid specifically for dual eligible beneficiaries at rates that were paid under Medicaid prior to being shifted to the federal prescription drug program is under development by House Oversight and Government Reform Committee Chairman Henry Waxman, D-Calif. The pending bill is an outgrowth of a report the committee released in July that said the government is paying 30 percent more for dual eligibles' drugs since drug coverage for the dual eligibles shifted from Medicaid to Medicare Part D under the Medicare Modernization Act (1"The Pink Sheet," July 28, 2008, p. 24). Brian Cohen, senior investigative counsel for the committee, said Sept. 23 during the AHIP annual Medicare and Medicaid conference that a bill could be introduced soon, but at the very latest early into the next Congress

Waxman to seek Medicaid prices for dual eligbles

Legislation that would set Medicare Part D drug prices paid specifically for dual eligible beneficiaries at rates that were paid under Medicaid prior to being shifted to the federal prescription drug program is under development by House Oversight and Government Reform Committee Chairman Henry Waxman, D-Calif. The pending bill is an outgrowth of a report the committee released in July that said the government is paying 30 percent more for dual eligibles' drugs since drug coverage for the dual eligibles shifted from Medicaid to Medicare Part D under the Medicare Modernization Act (1"The Pink Sheet," July 28, 2008, p. 24). Brian Cohen, senior investigative counsel for the committee, said Sept. 23 during the AHIP annual Medicare and Medicaid conference that a bill could be introduced soon, but at the very latest early into the next Congress

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS049924

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel